Navigation Links
Sequenom Appoints Two New Board Members
Date:12/16/2009

SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced the appointment of Dr. Kenneth Buechler and Mr. David Pendarvis to its board of directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

Kenneth F. Buechler, Ph.D., was president, chief scientific officer and co-founder of Biosite Incorporated. From 1988 to 1994, Dr. Buechler was Biosite's director of chemistry. Prior to forming Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated in San Diego. Dr. Buechler received his doctorate in biochemistry and his bachelor's degree in chemistry from Indiana University. Dr. Buechler sits on the boards of Quidel Corp., Sotera Wireless Inc., Adnavance Inc., and Astute Medical Inc.

David Pendarvis is senior vice president - organizational development, global general counsel and secretary of ResMed Inc., a medical device company focused on sleep-disordered breathing. He has been with ResMed since 2002. From 2000 until 2002, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP. Until 2000 he was a partner with Gibson, Dunn & Crutcher LLP, where he began working in 1986. From 1984 until 1986 he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis received his J.D. from the University of Texas School of Law, a MS in executive leadership from the University of San Diego, and a BA from Rice University.

"I am delighted that Ken and David have agreed to join our board of directors," said Dr. Harry Hixson, interim chief executive officer at Sequenom. "The talent and diverse expertise of our board has always been one of Sequenom's assets. With their proven industry executive experience, Ken and David are key additions to our team."

Dr. Buechler and Mr. Pendarvis join existing board members Dr. Ernst-Gunter Afting, Dr. Charles Cantor, Mr. John Fazio, Dr. Harry Hixson, Dr. Richard Lerner, Dr. Ronald Lindsay and Ms. Kathleen Wiltsey.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM(®) is a registered trademark of Sequenom, Inc.

SOURCE Sequenom, Inc.


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
2. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
5. SEQUENOM Announces Launch of MassARRAY Compact 96 System
6. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
7. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
8. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
9. Codexis Appoints Singapore Laboratories Managing Director
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):